A cell therapy preserves muscle structure and function in laboratory mice with a type of disease similar to Duchenne muscular ...

Hansa Biosciences’ Idefirix (imlifidase) has reduced patients’ antibodies to a level that allows dosing in patients with ...

Sarepta and Capricor learned of key regulatory decisions from the media and investors, and Duchenne muscular dystrophy ...

Alfie from Leigh has a muscle wasting condition and is looking for signed rugby shirts to auction off to help him live out ...

Dyne Therapeutics' DYNE-251 receives FDA breakthrough status for Duchenne muscular dystrophy treatment. Read more here.

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that the ...

Swedish biotech Hansa Biopharma on Friday released encouraging top-line results from three patients with Duchenne muscular ...

SRPT's Q2 report, set to arrive Aug. 6, is likely to have Elevidys updates, restructuring plans and sales outlook in sharp investor focus.

Wave Life Sciences (WVE) stock gains as Canaccord Genuity launches its coverage with a Buy, citing multiple catalysts for the ...

Precision BioSciences Inc., a clinical-stage company developing gene editing therapies for diseases with high unmet need, has ...

Investing.com -- Dyne Therapeutics Inc (NASDAQ: DYN) stock rose 3.6% after the company announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its ...

Dyne Therapeutics Inc (NASDAQ:DYN) stock climbed 3.6% following the announcement that the U.S. Food and Drug Administration ...